Clinical Benefit of Cognitive Behaviour Therapy (CBT) for Insomnia in Cancer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2003 by NHS Greater Clyde and Glasgow.
Recruitment status was  Active, not recruiting
Cancer Research UK
Information provided by:
NHS Greater Clyde and Glasgow Identifier:
First received: August 23, 2005
Last updated: October 25, 2005
Last verified: January 2003
The purpose of this study is to conduct a formal controlled evaluation of the potential benefits of CBT for insomnia in cancer patients.

Condition Intervention
Behavioral: Cognitive Behaviour Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised Controlled Clinical Effectiveness Trial of Cognitive Behaviour Therapy (CBT) Versus Treatment as Usual (TAU) for Insomnia in Cancer Patients

Further study details as provided by NHS Greater Clyde and Glasgow:

Study Start Date: January 2003
Estimated Study Completion Date: December 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Meets clinical criteria for insomnia.
  • Diagnosis of breast, prostate, colorectal or gynaecological cancer.
  • In follow-up phase with no further anti-cancer therapy planned.

Exclusion Criteria:

  • Anti-cancer chemotherapy or radiotherapy within 4 weeks of trial entry.
  • Evidence of sleep apnoea or other sleep disorder.
  • Evidence of untreated major depressive disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00134108

United Kingdom
North Glasgow and Grampian Trusts
Glasgow and Aberdeen, United Kingdom
Sponsors and Collaborators
NHS Greater Glasgow and Clyde
Cancer Research UK
Principal Investigator: Colin Espie, PhD University of Glasgow
  More Information Identifier: NCT00134108     History of Changes
Other Study ID Numbers: C8265/A3036 
Study First Received: August 23, 2005
Last Updated: October 25, 2005
Health Authority: United Kingdom: National Health Service processed this record on May 30, 2016